The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial

Blood

Volumn 92, Issue 10, 1998, Pages 3562-3568

  Blay, J Y ^a   Gomez, F ^b   Sebban, C ^b   Bachelot, T ^b   Biron, P ^b   Guglielmi, C ^b   Hagenbeek, A ^b   Somers, R ^b   Chauvin, F ^b   Philip, T ^b  

^a Centre L Berard   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MESNA;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CARMUSTINE; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FEMALE; HUMANS; ITALY; LIFE TABLES; LYMPHOMA, HIGH-GRADE; LYMPHOMA, INTERMEDIATE-GRADE; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032533888     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023, 1993
2. Cabanillas F, Hagemeister FB, McLaughin P, Velasquez WS, Riggs S, Fuller L, Smith T: Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5:407, 1987
3. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, Barlogie B: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117, 1988
4. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F: ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 12:1169, 1994
5. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ: IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60:693, 1982
6. Salles G, Shipp MA, Coiffier B: Chemotherapy of non-Hodgkin's aggressive lymphomas. Semin Hematol 31:46, 1994
7. Appelbaum FR, Herzig GP, Ziegler JL, Graw RG, Levine AS, Deisseroth AB: Successful engraftment of cryopreserved autologous bone-marrow in patients with malignant lymphoma. Blood 52:85, 1978
8. Philip T, Biron P, Maraninchi D, Gastaut JA, Herve P, Flesh Y, Goldstone AH, Souhami RL: Role of massive chemotherapy and ABMT in non-Hodgkin's malignant lymphoma. Lancet 2:391, 1984
9. Rosenberg SA: Autologous bone-marrow transplantation in non-Hodgkin's lymphoma. N Engl J Med 316:1541, 1987
10. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M, Laporte JP, Maraninchi D, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K: High-dose therapy and autologous bone-marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493, 1987
11. Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, Andrien F, Herbrecht R, Legros M, Devaux Y, Jaubert J, Pignon B, Michaux J-L, Humblt Y, Dupriez B, Thyss A, Lederlin P: Bone-marrow transplantation prolongs survival after relapse in aggressive lymphoma patients treated with the LNH84 regimen. J Clin Oncol 10:1615, 1992
12. Gisselbrecht C, Bosly A, Lepage E, Reyes F, Philip T, Haioun C, Tilly H, Coiffier B: Autologous hematopoietic stem cell transplantation in intermediate- and high-grade non-Hodgkin's lymphoma: A review. Ann Oncol 4:7, 1993 (suppl 1)
13. Vose JM, Anderson JR, Kessinger A, Bierman Ph, Coccia P, Reed EC, Gordon B, Armitage JO: High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 11:1846, 1993
14. Freedman AS, Nadler LM: Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? J Clin Oncol 11:1841, 1993
15. Rapoport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL, Packman CH, Eberly S, Sherman M, Tanner MA, Constine LS, DiPersio JF: One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 11:2351, 1993
16. Saez R, Dahlberg S, Appelbaum FR, Hartsock RJ, Lemaistre F, Coltman CA Jr, Fisher RI: Autologous bone-marrow transplantation in adults with non-Hodgkin's lymphoma: A Southwest Oncology Group Study. Hematol Oncol 12:75, 1994
17. Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonnefeld P, Gisselbrecht C, Cahn J-Y, Harousseau J-L, Coiffier B, Biron P, Mandelli F, Chauvin F: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non Hodgkin's lymphoma. N Engl J Med 333:1540, 1995
18. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987, 1993
19. Shipp MA: Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease? Blood 83:1165, 1994
20. Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Stat Assoc 53:457, 1958
21. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
22. Freeman DH: Applied Categorical Data Analysis. New York, NY, Dekker, 1987, p 279
23. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Brière J, Gaulard Ph, Reyes F: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor risk agressive non Hodgkin's lymphoma: Updated results of the prospective study LNH 87-2. J Clin Oncol 15:1131, 1997